Testo completo
Università Campus Bio-Medico
di Roma
HEAD MEDICAL ONCOLOGY
HOSPITAL CLÍNIC TENURE-TRACK PROFESSOR UNIVERSITY OF BARCELONA
Con il Patrocinio di:
CLICCA QUI PER PARTECIPARE
Documenti correlati
Trastuzumab (Hercep- tin, Roche) is a humanized monoclonal antibody that tar- gets HER2 and has been approved for clinical breast cancer therapy by the FDA for 15 years.
Sistémicas del Hospital Clínic de Barcelona y profesor asociado de Medicina de la Universidad de Barcelona, y Joan Carles Reverter Calatayud, especialista senior del Servicio
A phase II study of lapatinib for brain metastases in patients with HER2-overexpressing breast cancer following trastuzumab based systemic therapy and cranial radiotherapy:
To this end, we carried out a multicenter, retrospective analysis of HER2 positive early breast cancer patients treated with adjuvant chemotherapy alone or with chemo- therapy
Phase II study of a combination therapy of nivolumab, bevacizumab and paclitaxel in patients with HER2-negative metastatic breast cancer as a first-line treatment (WJOG9917B,
1L, first line; ABC, advanced breast cancer; CDK4/6, cyclin-dependent kinase 4/6; ET, endocrine therapy; FUL, fulvestrant; HER2, human epidermal growth factor receptor 2;
Phase III MONALEESA-7 Trial of Premenopausal Patients With HR+/HER2− Advanced Breast Cancer Treated With Endocrine Therapy ± Ribociclib: Overall Survival Results.. Presented By
Material and methods: We performed a retrospective analysis of 80 patients treated with at least first-line treatment for Her2 positive metastatic breast cancer (MBC) over the
